These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 17664490)

  • 1. Health economics in the Journal of Clinical Oncology and an evaluation of the indirect costs and benefits associated with adjuvant trastuzumab.
    de Lima Lopes G; Gluck S
    J Clin Oncol; 2007 Aug; 25(22):3382-3; author reply 3383. PubMed ID: 17664490
    [No Abstract]   [Full Text] [Related]  

  • 2. Do the large benefits justify the large costs of adjuvant breast cancer trastuzumab?
    Hillner BE; Smith TJ
    J Clin Oncol; 2007 Feb; 25(6):611-3. PubMed ID: 17308264
    [No Abstract]   [Full Text] [Related]  

  • 3. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer.
    Garrison LP; Lubeck D; Lalla D; Paton V; Dueck A; Perez EA
    Cancer; 2007 Aug; 110(3):489-98. PubMed ID: 17592827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cost-effectiveness of trastuzumab in the treatment of early stages breast cancer patients, in Portugal].
    Macedo A; Monteiro I; Andrade S; Cirrincione A; Ray J
    Acta Med Port; 2010; 23(3):475-82. PubMed ID: 20654267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trastuzumab in early stage breast cancer: a cost-effectiveness analysis for Belgium.
    Neyt M; Huybrechts M; Hulstaert F; Vrijens F; Ramaekers D
    Health Policy; 2008 Aug; 87(2):146-59. PubMed ID: 18164510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trastuzumab in breast cancer.
    Mastrianni DM
    N Engl J Med; 2006 Feb; 354(6):640-4; author reply 640-4. PubMed ID: 16470953
    [No Abstract]   [Full Text] [Related]  

  • 7. Rewarding value creation to promote innovation in oncology: The importance of considering the global product life cycle.
    Garrison LP
    Oncologist; 2010; 15 Suppl 1():49-57. PubMed ID: 20237218
    [No Abstract]   [Full Text] [Related]  

  • 8. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer.
    Liberato NL; Marchetti M; Barosi G
    J Clin Oncol; 2007 Feb; 25(6):625-33. PubMed ID: 17308267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cost/effectiveness analysis of adjuvant therapy with trastuzumab in patients with HER2 positive early breast cancer].
    Fagnani F; Colin X; Arveux P; Coudert B; Misset JL
    Bull Cancer; 2007 Jul; 94(7):711-20. PubMed ID: 17723955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost utility of sequential adjuvant trastuzumab for HER2/Neu-positive breast cancer.
    Reed SD; Schulman KA
    Value Health; 2009; 12(5):637-40. PubMed ID: 19473336
    [No Abstract]   [Full Text] [Related]  

  • 11. [High cost of trastuzumab for the treatment of mammary carcinoma in The Netherlands].
    Offerhaus L
    Ned Tijdschr Geneeskd; 2006 Jun; 150(25):1426-7; author reply 1427. PubMed ID: 16841595
    [No Abstract]   [Full Text] [Related]  

  • 12. Human epidermal growth factor receptor 2 expression in early breast cancer patients: a Swiss cost-effectiveness analysis of different predictive assay strategies.
    Blank PR; Schwenkglenks M; Moch H; Szucs TD
    Breast Cancer Res Treat; 2010 Nov; 124(2):497-507. PubMed ID: 20364309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trastuzumab for the treatment of primary breast cancer in HER2-positive women: a single technology appraisal.
    Ward S; Pilgrim H; Hind D
    Health Technol Assess; 2009 Jun; 13 Suppl 1():1-6. PubMed ID: 19567207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The economic value of innovative treatments over the product life cycle: the case of targeted trastuzumab therapy for breast cancer.
    Garrison LP; Veenstra DL
    Value Health; 2009; 12(8):1118-23. PubMed ID: 19624617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How much will Herceptin really cost?
    Barrett A; Roques T; Small M; Smith RD
    BMJ; 2006 Nov; 333(7578):1118-20. PubMed ID: 17124225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Do oncologists believe new cancer drugs offer good value?
    Nadler E; Eckert B; Neumann PJ
    Oncologist; 2006 Feb; 11(2):90-5. PubMed ID: 16476830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trastuzumab and capecitabine for metastatic breast cancer.
    Med Lett Drugs Ther; 1998 Nov; 40(1039):106-8. PubMed ID: 9814369
    [No Abstract]   [Full Text] [Related]  

  • 18. HER2 testing: the patent "genee" is out of the bottle.
    Goldman B
    CMAJ; 2007 May; 176(10):1443-4. PubMed ID: 17485697
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical and health economic outcomes of alternative HER2 test strategies for guiding adjuvant trastuzumab therapy.
    Lee JA; Shaheen M; Walke T; Daly M
    Expert Rev Pharmacoecon Outcomes Res; 2011 Jun; 11(3):325-41. PubMed ID: 21671702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Budget impact analysis of trastuzumab in early breast cancer: a hospital district perspective.
    Purmonen TT; Auvinen PK; Martikainen JA
    Int J Technol Assess Health Care; 2010 Apr; 26(2):163-9. PubMed ID: 20392319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.